| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Testing | 59 | 2024 | 1093 | 5.510 |
Why?
|
| Genetic Predisposition to Disease | 65 | 2025 | 3476 | 4.480 |
Why?
|
| Germ-Line Mutation | 32 | 2025 | 368 | 4.470 |
Why?
|
| Neoplasms | 45 | 2025 | 3023 | 4.120 |
Why?
|
| Genome, Human | 28 | 2025 | 1350 | 3.380 |
Why?
|
| Genetic Variation | 32 | 2024 | 1621 | 3.230 |
Why?
|
| Genomics | 43 | 2024 | 1675 | 3.190 |
Why?
|
| Databases, Genetic | 18 | 2024 | 501 | 2.620 |
Why?
|
| Neoplastic Syndromes, Hereditary | 12 | 2024 | 76 | 2.510 |
Why?
|
| Exome | 26 | 2024 | 1067 | 2.020 |
Why?
|
| Mutation | 52 | 2025 | 6292 | 1.940 |
Why?
|
| Genetic Counseling | 10 | 2024 | 244 | 1.870 |
Why?
|
| Genetic Association Studies | 9 | 2025 | 844 | 1.530 |
Why?
|
| Early Detection of Cancer | 10 | 2025 | 413 | 1.490 |
Why?
|
| Genetic Diseases, Inborn | 11 | 2024 | 453 | 1.480 |
Why?
|
| Sequence Analysis, DNA | 20 | 2022 | 1834 | 1.460 |
Why?
|
| Genes, BRCA1 | 9 | 2018 | 61 | 1.320 |
Why?
|
| Humans | 225 | 2025 | 133809 | 1.260 |
Why?
|
| Heterozygote | 9 | 2016 | 718 | 1.240 |
Why?
|
| Transcription Factors | 14 | 2025 | 2703 | 1.230 |
Why?
|
| Genetics, Medical | 10 | 2020 | 122 | 1.210 |
Why?
|
| Li-Fraumeni Syndrome | 4 | 2022 | 52 | 1.210 |
Why?
|
| Rothmund-Thomson Syndrome | 9 | 2019 | 47 | 1.180 |
Why?
|
| Child | 90 | 2025 | 25743 | 1.160 |
Why?
|
| Intellectual Disability | 3 | 2025 | 1076 | 1.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 14 | 2023 | 961 | 1.120 |
Why?
|
| Neurilemmoma | 2 | 2025 | 48 | 1.060 |
Why?
|
| Adenomatous Polyposis Coli | 7 | 2024 | 45 | 1.060 |
Why?
|
| Incidental Findings | 10 | 2023 | 128 | 1.050 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 4 | 2024 | 65 | 1.040 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2024 | 87 | 1.030 |
Why?
|
| Rhabdoid Tumor | 2 | 2025 | 56 | 1.020 |
Why?
|
| Leukemia | 4 | 2023 | 379 | 0.980 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2025 | 3 | 0.970 |
Why?
|
| SMARCB1 Protein | 1 | 2025 | 48 | 0.950 |
Why?
|
| Translocation, Genetic | 4 | 2015 | 362 | 0.950 |
Why?
|
| Abnormalities, Multiple | 6 | 2025 | 977 | 0.940 |
Why?
|
| Breast Neoplasms | 15 | 2018 | 2760 | 0.930 |
Why?
|
| Micrognathism | 1 | 2025 | 68 | 0.920 |
Why?
|
| Hand Deformities, Congenital | 1 | 2025 | 95 | 0.900 |
Why?
|
| Data Curation | 3 | 2024 | 14 | 0.900 |
Why?
|
| Neck | 1 | 2025 | 143 | 0.880 |
Why?
|
| Adenosine Triphosphatases | 7 | 2017 | 204 | 0.880 |
Why?
|
| Kidney Neoplasms | 6 | 2025 | 460 | 0.880 |
Why?
|
| Brain Neoplasms | 11 | 2025 | 1400 | 0.880 |
Why?
|
| Information Dissemination | 6 | 2024 | 198 | 0.860 |
Why?
|
| Face | 1 | 2025 | 190 | 0.860 |
Why?
|
| Saccharomyces cerevisiae | 7 | 2010 | 435 | 0.850 |
Why?
|
| Ovarian Neoplasms | 9 | 2022 | 464 | 0.830 |
Why?
|
| Germ Cells | 10 | 2024 | 203 | 0.810 |
Why?
|
| Computational Biology | 9 | 2018 | 888 | 0.790 |
Why?
|
| Skin Neoplasms | 3 | 2025 | 906 | 0.770 |
Why?
|
| DNA-Binding Proteins | 14 | 2023 | 2161 | 0.750 |
Why?
|
| Cell Cycle Proteins | 9 | 2016 | 695 | 0.740 |
Why?
|
| Repressor Proteins | 8 | 2019 | 869 | 0.740 |
Why?
|
| Neoplasm Proteins | 4 | 2019 | 717 | 0.730 |
Why?
|
| Genes, BRCA2 | 5 | 2018 | 49 | 0.730 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2017 | 808 | 0.710 |
Why?
|
| Disclosure | 6 | 2019 | 154 | 0.700 |
Why?
|
| Guidelines as Topic | 4 | 2017 | 201 | 0.680 |
Why?
|
| Disease | 2 | 2018 | 134 | 0.670 |
Why?
|
| Pharmacogenetics | 2 | 2023 | 196 | 0.670 |
Why?
|
| Rare Diseases | 2 | 2021 | 206 | 0.670 |
Why?
|
| RecQ Helicases | 8 | 2010 | 64 | 0.640 |
Why?
|
| DNA Helicases | 5 | 2023 | 251 | 0.640 |
Why?
|
| Phenotype | 18 | 2025 | 4530 | 0.630 |
Why?
|
| Oncologists | 4 | 2023 | 29 | 0.630 |
Why?
|
| Child, Preschool | 41 | 2025 | 14787 | 0.630 |
Why?
|
| Algorithms | 8 | 2024 | 1728 | 0.620 |
Why?
|
| Female | 90 | 2025 | 71587 | 0.620 |
Why?
|
| Laboratories | 2 | 2016 | 89 | 0.610 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2024 | 790 | 0.600 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2020 | 568 | 0.590 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2019 | 207 | 0.590 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2024 | 262 | 0.590 |
Why?
|
| Male | 81 | 2025 | 65830 | 0.580 |
Why?
|
| Molecular Sequence Annotation | 1 | 2018 | 162 | 0.570 |
Why?
|
| Adolescent | 44 | 2025 | 20542 | 0.570 |
Why?
|
| Colorectal Neoplasms | 6 | 2022 | 650 | 0.570 |
Why?
|
| Genetics, Population | 1 | 2018 | 198 | 0.560 |
Why?
|
| Rhabdomyosarcoma | 4 | 2024 | 209 | 0.560 |
Why?
|
| Infant | 36 | 2025 | 13148 | 0.560 |
Why?
|
| Jews | 5 | 2003 | 34 | 0.560 |
Why?
|
| Adult | 49 | 2025 | 31928 | 0.550 |
Why?
|
| Research Subjects | 2 | 2015 | 55 | 0.540 |
Why?
|
| Congenital Abnormalities | 4 | 2025 | 290 | 0.530 |
Why?
|
| Wilms Tumor | 3 | 2025 | 119 | 0.530 |
Why?
|
| BRCA1 Protein | 4 | 2024 | 82 | 0.530 |
Why?
|
| Parents | 5 | 2024 | 1058 | 0.530 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2017 | 34 | 0.530 |
Why?
|
| 5'-Nucleotidase | 1 | 2016 | 21 | 0.520 |
Why?
|
| Genetic Research | 3 | 2018 | 56 | 0.510 |
Why?
|
| Ethics, Medical | 3 | 2018 | 403 | 0.500 |
Why?
|
| Chromosome Deletion | 3 | 2010 | 664 | 0.490 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 2123 | 0.480 |
Why?
|
| Base Sequence | 16 | 2018 | 3171 | 0.480 |
Why?
|
| Nuclear Proteins | 7 | 2023 | 1334 | 0.470 |
Why?
|
| Peutz-Jeghers Syndrome | 3 | 2024 | 28 | 0.470 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 3 | 2001 | 28 | 0.450 |
Why?
|
| Ligases | 3 | 2001 | 48 | 0.450 |
Why?
|
| Neurofibromatosis 1 | 4 | 2017 | 64 | 0.450 |
Why?
|
| Genes, Neoplasm | 3 | 2010 | 90 | 0.440 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2020 | 2935 | 0.440 |
Why?
|
| DNA Copy Number Variations | 7 | 2022 | 1022 | 0.440 |
Why?
|
| Death | 1 | 2015 | 80 | 0.440 |
Why?
|
| Alleles | 12 | 2020 | 1706 | 0.430 |
Why?
|
| Decision Making | 8 | 2024 | 696 | 0.430 |
Why?
|
| Liver Neoplasms | 7 | 2025 | 1409 | 0.420 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2019 | 529 | 0.420 |
Why?
|
| Molecular Sequence Data | 13 | 2015 | 3970 | 0.420 |
Why?
|
| Antineoplastic Agents | 8 | 2021 | 1849 | 0.420 |
Why?
|
| Retinoblastoma | 4 | 2018 | 119 | 0.410 |
Why?
|
| Biomedical Research | 2 | 2016 | 556 | 0.410 |
Why?
|
| Growth Disorders | 3 | 2025 | 221 | 0.410 |
Why?
|
| DNA Repair | 6 | 2017 | 629 | 0.410 |
Why?
|
| Ribonuclease III | 2 | 2025 | 103 | 0.400 |
Why?
|
| Neutropenia | 3 | 2019 | 201 | 0.400 |
Why?
|
| MicroRNAs | 2 | 2025 | 951 | 0.400 |
Why?
|
| Software | 7 | 2018 | 737 | 0.380 |
Why?
|
| Saccharomyces cerevisiae Proteins | 4 | 2008 | 283 | 0.380 |
Why?
|
| Neurofibromatoses | 2 | 2025 | 10 | 0.380 |
Why?
|
| Genotype | 10 | 2025 | 2807 | 0.380 |
Why?
|
| Peroxidase | 2 | 2009 | 72 | 0.380 |
Why?
|
| DNA Repair-Deficiency Disorders | 2 | 2024 | 4 | 0.370 |
Why?
|
| Intestinal Polyposis | 2 | 2022 | 18 | 0.370 |
Why?
|
| Down Syndrome | 4 | 2023 | 230 | 0.360 |
Why?
|
| Gene Dosage | 3 | 2015 | 456 | 0.360 |
Why?
|
| Practice Guidelines as Topic | 7 | 2024 | 1330 | 0.350 |
Why?
|
| DNA Mutational Analysis | 9 | 2019 | 839 | 0.350 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2016 | 251 | 0.350 |
Why?
|
| Meningioma | 2 | 2025 | 142 | 0.340 |
Why?
|
| Risk Management | 1 | 2011 | 70 | 0.340 |
Why?
|
| Neuroblastoma | 5 | 2023 | 539 | 0.340 |
Why?
|
| DNA Damage | 6 | 2016 | 545 | 0.340 |
Why?
|
| Whole Genome Sequencing | 4 | 2023 | 327 | 0.340 |
Why?
|
| Receptors, Cell Surface | 2 | 2015 | 494 | 0.330 |
Why?
|
| Meningeal Neoplasms | 2 | 2025 | 217 | 0.330 |
Why?
|
| Aneuploidy | 2 | 2010 | 145 | 0.330 |
Why?
|
| Texas | 11 | 2024 | 3683 | 0.330 |
Why?
|
| Terminology as Topic | 2 | 2024 | 236 | 0.320 |
Why?
|
| Medicine | 1 | 2011 | 108 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2007 | 82 | 0.320 |
Why?
|
| Fungal Proteins | 2 | 2002 | 142 | 0.320 |
Why?
|
| Risk Assessment | 8 | 2024 | 3690 | 0.320 |
Why?
|
| Transcription, Genetic | 4 | 2005 | 1757 | 0.320 |
Why?
|
| Genes, Fungal | 2 | 2008 | 64 | 0.310 |
Why?
|
| Glioma | 3 | 2023 | 534 | 0.310 |
Why?
|
| Young Adult | 16 | 2025 | 9902 | 0.300 |
Why?
|
| Telomerase | 2 | 2020 | 180 | 0.300 |
Why?
|
| DNA Mismatch Repair | 3 | 2024 | 48 | 0.290 |
Why?
|
| Fanconi Anemia | 2 | 2017 | 45 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2008 | 43 | 0.290 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 72 | 0.290 |
Why?
|
| Leukemia, Myeloid | 2 | 2019 | 82 | 0.290 |
Why?
|
| Pediatrics | 2 | 2017 | 1216 | 0.290 |
Why?
|
| Chromosomal Instability | 1 | 2008 | 63 | 0.280 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2025 | 999 | 0.280 |
Why?
|
| Genes, p53 | 1 | 2008 | 234 | 0.280 |
Why?
|
| United States | 20 | 2025 | 11663 | 0.280 |
Why?
|
| Siblings | 2 | 2024 | 198 | 0.280 |
Why?
|
| Anaphase-Promoting Complex-Cyclosome | 4 | 2019 | 20 | 0.280 |
Why?
|
| Models, Theoretical | 1 | 2010 | 398 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2005 | 78 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2007 | 100 | 0.270 |
Why?
|
| Family | 4 | 2024 | 589 | 0.270 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2023 | 510 | 0.270 |
Why?
|
| Fanconi Anemia Complementation Group G Protein | 1 | 2006 | 2 | 0.270 |
Why?
|
| Peroxidases | 1 | 2006 | 28 | 0.270 |
Why?
|
| Gene Deletion | 5 | 2018 | 809 | 0.260 |
Why?
|
| Mutation, Missense | 4 | 2023 | 928 | 0.260 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2021 | 128 | 0.260 |
Why?
|
| MutS Homolog 2 Protein | 3 | 2022 | 40 | 0.250 |
Why?
|
| MutL Protein Homolog 1 | 3 | 2022 | 54 | 0.250 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 234 | 0.250 |
Why?
|
| Ubiquitins | 3 | 2001 | 44 | 0.250 |
Why?
|
| Risk | 3 | 2021 | 831 | 0.250 |
Why?
|
| Chromosome Mapping | 7 | 2023 | 1124 | 0.250 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 319 | 0.250 |
Why?
|
| Pedigree | 10 | 2016 | 1695 | 0.250 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2015 | 615 | 0.240 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2025 | 15 | 0.240 |
Why?
|
| Nerve Tissue Proteins | 2 | 2017 | 1161 | 0.240 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 295 | 0.240 |
Why?
|
| Craniofacial Abnormalities | 2 | 2017 | 250 | 0.240 |
Why?
|
| Pineal Gland | 1 | 2025 | 22 | 0.240 |
Why?
|
| Pinealoma | 1 | 2025 | 23 | 0.240 |
Why?
|
| DNA Repair Enzymes | 2 | 2015 | 48 | 0.240 |
Why?
|
| Middle Aged | 21 | 2025 | 29350 | 0.240 |
Why?
|
| Physicians, Family | 2 | 2003 | 38 | 0.240 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2025 | 34 | 0.240 |
Why?
|
| Evidence-Based Practice | 2 | 2016 | 116 | 0.240 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2025 | 23 | 0.230 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2019 | 40 | 0.230 |
Why?
|
| Medical Oncology | 5 | 2018 | 244 | 0.230 |
Why?
|
| Syndactyly | 1 | 2005 | 24 | 0.230 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2024 | 30 | 0.230 |
Why?
|
| Osteosarcoma | 2 | 2008 | 263 | 0.230 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2025 | 147 | 0.230 |
Why?
|
| Mass Screening | 3 | 2022 | 832 | 0.230 |
Why?
|
| Language Development Disorders | 2 | 2017 | 179 | 0.230 |
Why?
|
| Risk Factors | 15 | 2025 | 11071 | 0.220 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2016 | 176 | 0.220 |
Why?
|
| Social Justice | 1 | 2025 | 65 | 0.220 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2004 | 20 | 0.220 |
Why?
|
| Syndrome | 7 | 2016 | 1165 | 0.220 |
Why?
|
| Truth Disclosure | 2 | 2017 | 105 | 0.220 |
Why?
|
| Conserved Sequence | 3 | 2018 | 298 | 0.220 |
Why?
|
| Cell Cycle | 6 | 2019 | 627 | 0.220 |
Why?
|
| Cell Nucleus | 1 | 2006 | 687 | 0.220 |
Why?
|
| Pharmacogenomic Variants | 1 | 2023 | 38 | 0.210 |
Why?
|
| Beckwith-Wiedemann Syndrome | 1 | 2023 | 16 | 0.210 |
Why?
|
| Klinefelter Syndrome | 1 | 2023 | 18 | 0.210 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 65 | 0.210 |
Why?
|
| Immunoprecipitation | 3 | 2011 | 204 | 0.210 |
Why?
|
| Genome-Wide Association Study | 4 | 2019 | 1872 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2024 | 129 | 0.200 |
Why?
|
| Genomic Instability | 1 | 2024 | 243 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 1311 | 0.200 |
Why?
|
| Carcinoma, Small Cell | 1 | 2023 | 50 | 0.200 |
Why?
|
| Chromosome Breakage | 2 | 2016 | 167 | 0.200 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2025 | 233 | 0.200 |
Why?
|
| DNA | 7 | 2010 | 1676 | 0.200 |
Why?
|
| Chromatids | 1 | 2002 | 41 | 0.200 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 40 | 0.200 |
Why?
|
| Sarcoma | 2 | 2016 | 209 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 2 | 2024 | 164 | 0.200 |
Why?
|
| Histone Deacetylases | 1 | 2003 | 122 | 0.200 |
Why?
|
| DNA, Neoplasm | 3 | 2015 | 317 | 0.200 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 96 | 0.200 |
Why?
|
| HeLa Cells | 6 | 2006 | 827 | 0.200 |
Why?
|
| Cadherins | 2 | 2022 | 186 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2025 | 619 | 0.190 |
Why?
|
| Microsatellite Instability | 2 | 2024 | 43 | 0.190 |
Why?
|
| Karyotyping | 4 | 2009 | 324 | 0.190 |
Why?
|
| Loss of Function Mutation | 1 | 2023 | 159 | 0.190 |
Why?
|
| Bloom Syndrome | 2 | 2017 | 5 | 0.190 |
Why?
|
| Thyroid Neoplasms | 2 | 2025 | 255 | 0.190 |
Why?
|
| Societies, Medical | 4 | 2018 | 758 | 0.190 |
Why?
|
| Testicular Neoplasms | 1 | 2023 | 135 | 0.190 |
Why?
|
| Precision Medicine | 6 | 2024 | 356 | 0.190 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 3057 | 0.190 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 17 | 0.190 |
Why?
|
| Infant, Newborn | 13 | 2025 | 8582 | 0.190 |
Why?
|
| Data Collection | 3 | 2020 | 397 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2024 | 894 | 0.180 |
Why?
|
| Patients | 3 | 2018 | 127 | 0.180 |
Why?
|
| MyoD Protein | 1 | 2021 | 26 | 0.180 |
Why?
|
| BRCA2 Protein | 3 | 2020 | 52 | 0.180 |
Why?
|
| Antigens, CD | 2 | 2022 | 452 | 0.180 |
Why?
|
| Multilingualism | 2 | 2018 | 43 | 0.180 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2001 | 69 | 0.180 |
Why?
|
| Fibroblasts | 5 | 2016 | 921 | 0.180 |
Why?
|
| Mitochondria | 1 | 2006 | 741 | 0.180 |
Why?
|
| Oxidative Stress | 1 | 2006 | 869 | 0.180 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2014 | 59 | 0.180 |
Why?
|
| Gene Frequency | 5 | 2024 | 778 | 0.180 |
Why?
|
| Pathologists | 2 | 2018 | 30 | 0.180 |
Why?
|
| Incidence | 9 | 2023 | 3393 | 0.170 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2020 | 31 | 0.170 |
Why?
|
| Trans-Activators | 1 | 2025 | 830 | 0.170 |
Why?
|
| Professional-Family Relations | 2 | 2018 | 96 | 0.170 |
Why?
|
| Smad4 Protein | 1 | 2020 | 58 | 0.170 |
Why?
|
| Chromosome Aberrations | 2 | 2017 | 626 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1353 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 1004 | 0.170 |
Why?
|
| Chromosome Duplication | 2 | 2011 | 148 | 0.170 |
Why?
|
| Phosphoproteins | 1 | 2002 | 454 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2001 | 102 | 0.170 |
Why?
|
| Cell Line | 8 | 2019 | 2837 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2010 | 149 | 0.170 |
Why?
|
| Colectomy | 1 | 2020 | 82 | 0.170 |
Why?
|
| Health Care Surveys | 2 | 2011 | 292 | 0.160 |
Why?
|
| Transfection | 4 | 2006 | 1088 | 0.160 |
Why?
|
| Watchful Waiting | 1 | 2020 | 77 | 0.160 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 21 | 0.160 |
Why?
|
| Mammography | 1 | 2000 | 132 | 0.160 |
Why?
|
| Apc1 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2019 | 3 | 0.160 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 32 | 0.160 |
Why?
|
| Models, Genetic | 3 | 2018 | 789 | 0.160 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2019 | 33 | 0.160 |
Why?
|
| Health Behavior | 2 | 2014 | 402 | 0.160 |
Why?
|
| Patient Compliance | 2 | 2000 | 479 | 0.160 |
Why?
|
| Animals | 14 | 2021 | 36364 | 0.160 |
Why?
|
| Ependymoma | 1 | 2021 | 173 | 0.160 |
Why?
|
| Tandem Repeat Sequences | 2 | 2016 | 38 | 0.160 |
Why?
|
| Registries | 6 | 2025 | 1562 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2015 | 95 | 0.160 |
Why?
|
| Cell Survival | 5 | 2016 | 890 | 0.160 |
Why?
|
| Attitude of Health Personnel | 2 | 2003 | 712 | 0.160 |
Why?
|
| Surveys and Questionnaires | 7 | 2024 | 3985 | 0.160 |
Why?
|
| Nutrition Disorders | 1 | 1999 | 32 | 0.160 |
Why?
|
| Telomere Shortening | 1 | 2019 | 36 | 0.150 |
Why?
|
| Physicians | 3 | 2018 | 630 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 1326 | 0.150 |
Why?
|
| Blood Proteins | 1 | 1999 | 135 | 0.150 |
Why?
|
| Vertebrates | 1 | 2018 | 41 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2021 | 327 | 0.150 |
Why?
|
| Hepatoblastoma | 2 | 2020 | 184 | 0.150 |
Why?
|
| Cyclic AMP | 1 | 1999 | 262 | 0.150 |
Why?
|
| Sequence Alignment | 3 | 2011 | 633 | 0.150 |
Why?
|
| Retinal Neoplasms | 2 | 2011 | 104 | 0.150 |
Why?
|
| Optic Nerve Glioma | 2 | 2017 | 22 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 447 | 0.150 |
Why?
|
| Prognosis | 6 | 2025 | 5068 | 0.150 |
Why?
|
| Protein Interaction Mapping | 1 | 2018 | 94 | 0.150 |
Why?
|
| Empathy | 1 | 2018 | 63 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2018 | 58 | 0.150 |
Why?
|
| Pyrimidines | 1 | 2021 | 417 | 0.140 |
Why?
|
| Intensive Care, Neonatal | 1 | 2018 | 57 | 0.140 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 76 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2006 | 801 | 0.140 |
Why?
|
| Cultural Competency | 1 | 2018 | 54 | 0.140 |
Why?
|
| Genetic Privacy | 1 | 2018 | 43 | 0.140 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 138 | 0.140 |
Why?
|
| Mitosis | 4 | 2016 | 194 | 0.140 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2017 | 20 | 0.140 |
Why?
|
| Communication | 2 | 2018 | 541 | 0.140 |
Why?
|
| Antigens, Nuclear | 1 | 2017 | 57 | 0.140 |
Why?
|
| Indians, North American | 2 | 2010 | 65 | 0.140 |
Why?
|
| Forkhead Transcription Factors | 4 | 2006 | 382 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 324 | 0.140 |
Why?
|
| Child Health Services | 1 | 2018 | 88 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 132 | 0.140 |
Why?
|
| Electronic Health Records | 2 | 2015 | 789 | 0.140 |
Why?
|
| Hodgkin Disease | 2 | 2019 | 298 | 0.140 |
Why?
|
| Consensus | 2 | 2018 | 736 | 0.140 |
Why?
|
| Language | 1 | 2018 | 218 | 0.140 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 42 | 0.130 |
Why?
|
| G2 Phase | 4 | 2006 | 45 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2015 | 374 | 0.130 |
Why?
|
| Genetic Linkage | 2 | 2015 | 480 | 0.130 |
Why?
|
| HEK293 Cells | 2 | 2017 | 812 | 0.130 |
Why?
|
| Bone Diseases, Developmental | 1 | 2017 | 59 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 590 | 0.130 |
Why?
|
| Hypertrophy | 1 | 2017 | 104 | 0.130 |
Why?
|
| Stomach Neoplasms | 1 | 2022 | 559 | 0.130 |
Why?
|
| Microcephaly | 2 | 2017 | 347 | 0.130 |
Why?
|
| Medical History Taking | 2 | 2020 | 118 | 0.130 |
Why?
|
| B-Lymphocytes | 2 | 2016 | 550 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2003 | 763 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 101 | 0.130 |
Why?
|
| Age Factors | 4 | 2020 | 2978 | 0.130 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2006 | 67 | 0.130 |
Why?
|
| Boronic Acids | 2 | 2007 | 48 | 0.130 |
Why?
|
| Glutathione Transferase | 2 | 2009 | 163 | 0.130 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2016 | 30 | 0.130 |
Why?
|
| Feeding and Eating Disorders | 1 | 2017 | 76 | 0.130 |
Why?
|
| Limb Deformities, Congenital | 1 | 2017 | 110 | 0.130 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2018 | 181 | 0.120 |
Why?
|
| Pyrazines | 2 | 2007 | 73 | 0.120 |
Why?
|
| Phylogeny | 1 | 2018 | 787 | 0.120 |
Why?
|
| Haploinsufficiency | 1 | 2017 | 274 | 0.120 |
Why?
|
| National Human Genome Research Institute (U.S.) | 4 | 2018 | 19 | 0.120 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 21 | 0.120 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 1912 | 0.120 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 33 | 0.120 |
Why?
|
| Zonula Occludens-2 Protein | 1 | 2015 | 7 | 0.120 |
Why?
|
| Apoptosis | 1 | 2002 | 1931 | 0.120 |
Why?
|
| Amino Acid Sequence | 5 | 2006 | 2785 | 0.120 |
Why?
|
| Plasmids | 4 | 2005 | 527 | 0.120 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 64 | 0.120 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2016 | 114 | 0.120 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2016 | 58 | 0.120 |
Why?
|
| Interview, Psychological | 1 | 2015 | 102 | 0.120 |
Why?
|
| Cohort Studies | 6 | 2024 | 5175 | 0.120 |
Why?
|
| DCC Receptor | 1 | 2015 | 5 | 0.120 |
Why?
|
| DNA, Complementary | 3 | 2003 | 472 | 0.120 |
Why?
|
| Parenting | 1 | 2019 | 347 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2017 | 397 | 0.120 |
Why?
|
| Open Reading Frames | 2 | 2010 | 220 | 0.120 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 65 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 240 | 0.120 |
Why?
|
| Telomere | 1 | 2016 | 230 | 0.120 |
Why?
|
| Chromosome Breakpoints | 1 | 2015 | 82 | 0.120 |
Why?
|
| Cyclin B | 1 | 2014 | 23 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2015 | 64 | 0.120 |
Why?
|
| Oncogene Fusion | 1 | 2014 | 26 | 0.110 |
Why?
|
| Chromosome Disorders | 1 | 2017 | 315 | 0.110 |
Why?
|
| Medulloblastoma | 1 | 2019 | 571 | 0.110 |
Why?
|
| INDEL Mutation | 1 | 2015 | 94 | 0.110 |
Why?
|
| Telomere-Binding Proteins | 1 | 2014 | 46 | 0.110 |
Why?
|
| Protein Conformation | 2 | 2016 | 873 | 0.110 |
Why?
|
| Ophthalmology | 1 | 2017 | 217 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2017 | 216 | 0.110 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2020 | 37 | 0.110 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 3 | 2001 | 41 | 0.110 |
Why?
|
| Retrospective Studies | 7 | 2024 | 17457 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2015 | 123 | 0.110 |
Why?
|
| Lymphedema | 1 | 2014 | 21 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2015 | 145 | 0.110 |
Why?
|
| Neutrophils | 1 | 2016 | 401 | 0.110 |
Why?
|
| RNA, Messenger | 3 | 2015 | 2900 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2009 | 790 | 0.110 |
Why?
|
| Genes, Dominant | 2 | 2013 | 254 | 0.110 |
Why?
|
| Genes, Recessive | 2 | 2013 | 194 | 0.110 |
Why?
|
| Aged | 10 | 2020 | 21701 | 0.110 |
Why?
|
| PAX5 Transcription Factor | 1 | 2013 | 15 | 0.110 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2017 | 486 | 0.110 |
Why?
|
| Retinoblastoma Protein | 2 | 2011 | 86 | 0.110 |
Why?
|
| Biomarkers, Tumor | 3 | 2023 | 1718 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2012 | 577 | 0.100 |
Why?
|
| Adenoma | 1 | 2015 | 142 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2024 | 6660 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2013 | 39 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2011 | 225 | 0.100 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2014 | 78 | 0.100 |
Why?
|
| DNA Primers | 4 | 2011 | 671 | 0.100 |
Why?
|
| Muscle Hypotonia | 1 | 2014 | 196 | 0.100 |
Why?
|
| Support Vector Machine | 1 | 2012 | 22 | 0.100 |
Why?
|
| Penetrance | 3 | 2018 | 111 | 0.100 |
Why?
|
| Intestinal Neoplasms | 1 | 2013 | 41 | 0.100 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 392 | 0.100 |
Why?
|
| Age of Onset | 3 | 2024 | 635 | 0.100 |
Why?
|
| Proteins | 1 | 2018 | 1087 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2014 | 136 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2017 | 1046 | 0.100 |
Why?
|
| Ultraviolet Rays | 3 | 2008 | 215 | 0.100 |
Why?
|
| Models, Molecular | 1 | 2016 | 1136 | 0.100 |
Why?
|
| Attitude | 1 | 2013 | 122 | 0.100 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 1489 | 0.100 |
Why?
|
| Health Surveys | 1 | 2013 | 258 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2016 | 399 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 1632 | 0.100 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2006 | 676 | 0.100 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 3 | 2017 | 11 | 0.100 |
Why?
|
| Medical Informatics | 1 | 2013 | 113 | 0.100 |
Why?
|
| Mutagenicity Tests | 2 | 2008 | 35 | 0.100 |
Why?
|
| Patient Education as Topic | 3 | 2002 | 462 | 0.100 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 140 | 0.090 |
Why?
|
| Genes, Retinoblastoma | 1 | 2011 | 21 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 3 | 2009 | 1414 | 0.090 |
Why?
|
| Histones | 3 | 2011 | 569 | 0.090 |
Why?
|
| Research Personnel | 1 | 2013 | 136 | 0.090 |
Why?
|
| DNA Replication | 3 | 2024 | 362 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2001 | 388 | 0.090 |
Why?
|
| Ganglioglioma | 1 | 2011 | 22 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 181 | 0.090 |
Why?
|
| Oncogenes | 2 | 2011 | 179 | 0.090 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2013 | 194 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2011 | 114 | 0.090 |
Why?
|
| Intestine, Small | 1 | 2013 | 317 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2017 | 1606 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 165 | 0.080 |
Why?
|
| Referral and Consultation | 4 | 2014 | 570 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5503 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2025 | 1478 | 0.080 |
Why?
|
| Organisms, Genetically Modified | 1 | 2010 | 11 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 5 | 2005 | 1102 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2006 | 3748 | 0.080 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 175 | 0.080 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 608 | 0.080 |
Why?
|
| Mutagenesis, Insertional | 2 | 2008 | 157 | 0.080 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2009 | 27 | 0.080 |
Why?
|
| Globins | 2 | 1986 | 36 | 0.080 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2011 | 121 | 0.080 |
Why?
|
| Genes, Regulator | 2 | 1986 | 57 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2015 | 1764 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2014 | 527 | 0.080 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2010 | 142 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2018 | 1488 | 0.080 |
Why?
|
| Zinc Fingers | 1 | 2009 | 124 | 0.080 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 107 | 0.080 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2010 | 151 | 0.070 |
Why?
|
| Simian virus 40 | 2 | 1986 | 196 | 0.070 |
Why?
|
| Europe | 3 | 2018 | 384 | 0.070 |
Why?
|
| Translating | 2 | 2018 | 31 | 0.070 |
Why?
|
| Kinetochores | 1 | 2008 | 4 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2017 | 1702 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2008 | 43 | 0.070 |
Why?
|
| Chromosomes, Fungal | 1 | 2008 | 49 | 0.070 |
Why?
|
| Mutagens | 1 | 2008 | 84 | 0.070 |
Why?
|
| Megakaryocytes | 1 | 2008 | 45 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2017 | 4893 | 0.070 |
Why?
|
| Clone Cells | 1 | 2008 | 180 | 0.070 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2007 | 10 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 397 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1996 | 862 | 0.070 |
Why?
|
| Janus Kinase 2 | 1 | 2008 | 131 | 0.070 |
Why?
|
| Enhancer Elements, Genetic | 2 | 1986 | 315 | 0.070 |
Why?
|
| Prevalence | 3 | 2018 | 2655 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2008 | 263 | 0.070 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2007 | 94 | 0.070 |
Why?
|
| Point Mutation | 1 | 2008 | 360 | 0.070 |
Why?
|
| Demography | 2 | 1999 | 247 | 0.070 |
Why?
|
| Nuclear Localization Signals | 1 | 2006 | 16 | 0.070 |
Why?
|
| Peroxiredoxin III | 1 | 2006 | 2 | 0.070 |
Why?
|
| DNA Transposable Elements | 1 | 2008 | 188 | 0.070 |
Why?
|
| Peroxiredoxins | 1 | 2006 | 9 | 0.070 |
Why?
|
| Cisplatin | 2 | 2008 | 286 | 0.070 |
Why?
|
| Sequence Analysis | 2 | 2019 | 54 | 0.070 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2006 | 4 | 0.070 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2006 | 67 | 0.070 |
Why?
|
| Mitomycin | 1 | 2006 | 53 | 0.070 |
Why?
|
| Calpain | 1 | 2006 | 43 | 0.060 |
Why?
|
| Gene Expression | 3 | 2001 | 1614 | 0.060 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 1986 | 25 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 644 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 132 | 0.060 |
Why?
|
| COS Cells | 1 | 2006 | 283 | 0.060 |
Why?
|
| Physician-Patient Relations | 3 | 2018 | 446 | 0.060 |
Why?
|
| Exons | 2 | 2016 | 834 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2017 | 3165 | 0.060 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 129 | 0.060 |
Why?
|
| Son of Sevenless Proteins | 1 | 2005 | 5 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2006 | 433 | 0.060 |
Why?
|
| Ubiquitin | 1 | 2006 | 148 | 0.060 |
Why?
|
| Cell Division | 3 | 2006 | 774 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 1070 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 136 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2006 | 302 | 0.060 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 465 | 0.060 |
Why?
|
| Live Birth | 1 | 2025 | 70 | 0.060 |
Why?
|
| Luciferases | 1 | 2005 | 137 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 7194 | 0.060 |
Why?
|
| Genetic Markers | 2 | 1998 | 631 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 400 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2003 | 74 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 338 | 0.060 |
Why?
|
| Radius | 1 | 2005 | 34 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 1999 | 912 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2009 | 1596 | 0.060 |
Why?
|
| Patched-1 Receptor | 1 | 2025 | 50 | 0.060 |
Why?
|
| Gene Regulatory Networks | 1 | 2008 | 396 | 0.060 |
Why?
|
| Zinc Finger Protein Gli3 | 1 | 2005 | 8 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 100 | 0.060 |
Why?
|
| Lymphoma | 1 | 2008 | 335 | 0.060 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 1883 | 0.060 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2005 | 76 | 0.060 |
Why?
|
| Ikaros Transcription Factor | 1 | 2005 | 32 | 0.060 |
Why?
|
| Informed Consent | 2 | 2018 | 345 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2006 | 440 | 0.060 |
Why?
|
| Disease Management | 2 | 2019 | 560 | 0.060 |
Why?
|
| Amino Acid Substitution | 2 | 2020 | 412 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2004 | 123 | 0.060 |
Why?
|
| Cyclins | 1 | 2004 | 104 | 0.060 |
Why?
|
| Binding Sites | 2 | 2006 | 1369 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1406 | 0.060 |
Why?
|
| Colonoscopy | 2 | 2020 | 250 | 0.060 |
Why?
|
| Motivation | 2 | 2013 | 331 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2011 | 1147 | 0.060 |
Why?
|
| Acute Disease | 2 | 2018 | 1187 | 0.050 |
Why?
|
| Logistic Models | 2 | 1999 | 1906 | 0.050 |
Why?
|
| Family Health | 3 | 2016 | 267 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 567 | 0.050 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2005 | 119 | 0.050 |
Why?
|
| Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2003 | 5 | 0.050 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2003 | 38 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 1735 | 0.050 |
Why?
|
| Spindle Apparatus | 1 | 2003 | 50 | 0.050 |
Why?
|
| Blotting, Southern | 1 | 2003 | 222 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2005 | 1136 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2005 | 273 | 0.050 |
Why?
|
| Anxiety | 2 | 2000 | 992 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2007 | 271 | 0.050 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 13 | 0.050 |
Why?
|
| Craniosynostoses | 1 | 2005 | 134 | 0.050 |
Why?
|
| Caspase Inhibitors | 1 | 2002 | 35 | 0.050 |
Why?
|
| Prostaglandins | 1 | 2002 | 48 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2017 | 2539 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 130 | 0.050 |
Why?
|
| Minority Groups | 1 | 2024 | 255 | 0.050 |
Why?
|
| Diseases in Twins | 1 | 2003 | 99 | 0.050 |
Why?
|
| Mice | 4 | 2021 | 18876 | 0.050 |
Why?
|
| Etoposide | 1 | 2002 | 120 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3843 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 330 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 159 | 0.050 |
Why?
|
| Larva | 2 | 2017 | 262 | 0.050 |
Why?
|
| 3T3 Cells | 1 | 2002 | 123 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2002 | 327 | 0.050 |
Why?
|
| Caspases | 1 | 2002 | 167 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1622 | 0.050 |
Why?
|
| Genes, myc | 1 | 2002 | 107 | 0.050 |
Why?
|
| Cell Nucleolus | 1 | 2001 | 50 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2023 | 336 | 0.050 |
Why?
|
| Receptor, trkB | 1 | 2021 | 25 | 0.050 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2001 | 32 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2015 | 317 | 0.050 |
Why?
|
| Recombination, Genetic | 2 | 2016 | 452 | 0.050 |
Why?
|
| Cytogenetic Analysis | 1 | 2001 | 82 | 0.050 |
Why?
|
| Virulence | 1 | 2022 | 279 | 0.040 |
Why?
|
| Protein Binding | 1 | 2005 | 1834 | 0.040 |
Why?
|
| Introns | 1 | 2002 | 313 | 0.040 |
Why?
|
| Reference Values | 2 | 2001 | 744 | 0.040 |
Why?
|
| Likelihood Functions | 2 | 2013 | 121 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2001 | 123 | 0.040 |
Why?
|
| Microsatellite Repeats | 2 | 2005 | 239 | 0.040 |
Why?
|
| Trisomy | 1 | 2001 | 112 | 0.040 |
Why?
|
| Succinate Dehydrogenase | 1 | 2020 | 9 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2002 | 250 | 0.040 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2020 | 12 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 112 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 818 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 1135 | 0.040 |
Why?
|
| Patient Participation | 1 | 2023 | 234 | 0.040 |
Why?
|
| Burkitt Lymphoma | 1 | 2001 | 142 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2020 | 104 | 0.040 |
Why?
|
| Homozygote | 2 | 2016 | 560 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 217 | 0.040 |
Why?
|
| RNA Helicases | 1 | 2020 | 69 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2005 | 2657 | 0.040 |
Why?
|
| Activating Transcription Factors | 1 | 1999 | 4 | 0.040 |
Why?
|
| Cyclic AMP Response Element Modulator | 1 | 1999 | 25 | 0.040 |
Why?
|
| Test Anxiety Scale | 1 | 1999 | 2 | 0.040 |
Why?
|
| Time Factors | 3 | 2011 | 6584 | 0.040 |
Why?
|
| Marfan Syndrome | 1 | 2001 | 144 | 0.040 |
Why?
|
| Occult Blood | 1 | 1999 | 32 | 0.040 |
Why?
|
| Wasting Syndrome | 1 | 1999 | 25 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2001 | 290 | 0.040 |
Why?
|
| Multienzyme Complexes | 1 | 1999 | 88 | 0.040 |
Why?
|
| Social Responsibility | 1 | 2019 | 83 | 0.040 |
Why?
|
| Linguistics | 1 | 2018 | 20 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2001 | 724 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 432 | 0.040 |
Why?
|
| Peptides | 1 | 2002 | 861 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1999 | 119 | 0.040 |
Why?
|
| Endopeptidases | 1 | 1999 | 118 | 0.040 |
Why?
|
| Diploidy | 2 | 2008 | 39 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2001 | 374 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2018 | 41 | 0.040 |
Why?
|
| Genetic Carrier Screening | 1 | 1998 | 72 | 0.040 |
Why?
|
| Physical Examination | 1 | 1999 | 164 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 30 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 30 | 0.040 |
Why?
|
| Confidentiality | 1 | 1999 | 106 | 0.040 |
Why?
|
| Parental Consent | 1 | 2018 | 23 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 648 | 0.040 |
Why?
|
| Spermatogenesis | 1 | 1999 | 172 | 0.040 |
Why?
|
| Computer Security | 1 | 2018 | 29 | 0.040 |
Why?
|
| Intention | 1 | 2018 | 95 | 0.040 |
Why?
|
| Kinetics | 2 | 1997 | 1354 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3639 | 0.040 |
Why?
|
| Infant Care | 1 | 2017 | 47 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 135 | 0.040 |
Why?
|
| Body Height | 1 | 1999 | 231 | 0.040 |
Why?
|
| Physician's Role | 1 | 1999 | 171 | 0.030 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2017 | 7 | 0.030 |
Why?
|
| Guatemala | 1 | 2017 | 63 | 0.030 |
Why?
|
| Ataxia Telangiectasia | 1 | 2017 | 16 | 0.030 |
Why?
|
| Washington | 1 | 2017 | 35 | 0.030 |
Why?
|
| Social Behavior | 1 | 2019 | 230 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 291 | 0.030 |
Why?
|
| Power Plants | 1 | 1997 | 1 | 0.030 |
Why?
|
| Radioactive Fallout | 1 | 1997 | 1 | 0.030 |
Why?
|
| Radioactive Hazard Release | 1 | 1997 | 1 | 0.030 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2017 | 32 | 0.030 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1997 | 3 | 0.030 |
Why?
|
| Germany | 1 | 1997 | 74 | 0.030 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2017 | 78 | 0.030 |
Why?
|
| Philadelphia Chromosome | 1 | 2017 | 43 | 0.030 |
Why?
|
| Radiotherapy | 2 | 2014 | 148 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 2157 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 1997 | 67 | 0.030 |
Why?
|
| Nutritional Status | 1 | 1999 | 328 | 0.030 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2017 | 124 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 2017 | 101 | 0.030 |
Why?
|
| Eye | 1 | 2018 | 246 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 88 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 110 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1997 | 86 | 0.030 |
Why?
|
| Everolimus | 1 | 2016 | 50 | 0.030 |
Why?
|
| Population Groups | 1 | 2016 | 31 | 0.030 |
Why?
|
| Chromosome Segregation | 1 | 2016 | 67 | 0.030 |
Why?
|
| Bortezomib | 2 | 2007 | 72 | 0.030 |
Why?
|
| Research Report | 1 | 2016 | 79 | 0.030 |
Why?
|
| Meiosis | 1 | 2016 | 115 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2001 | 1065 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1997 | 353 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 308 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 1190 | 0.030 |
Why?
|
| Chromosomes | 1 | 2016 | 165 | 0.030 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2015 | 5 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 3064 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2017 | 243 | 0.030 |
Why?
|
| Templates, Genetic | 1 | 1995 | 97 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1995 | 27 | 0.030 |
Why?
|
| Utah | 1 | 2015 | 81 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2005 | 90 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 462 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2018 | 404 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 24 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 212 | 0.030 |
Why?
|
| G1 Phase | 1 | 1995 | 67 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 244 | 0.030 |
Why?
|
| Epigenomics | 1 | 2016 | 195 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2016 | 197 | 0.030 |
Why?
|
| Body Weight | 1 | 1999 | 1034 | 0.030 |
Why?
|
| Zebrafish | 1 | 2017 | 417 | 0.030 |
Why?
|
| Caffeine | 1 | 1995 | 71 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 292 | 0.030 |
Why?
|
| Sirolimus | 1 | 2016 | 253 | 0.030 |
Why?
|
| Recombinant Proteins | 3 | 2006 | 1440 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 456 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1993 | 90 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2015 | 371 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1993 | 65 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 538 | 0.030 |
Why?
|
| Genes, X-Linked | 1 | 2013 | 63 | 0.030 |
Why?
|
| Bile Acids and Salts | 1 | 2016 | 259 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2013 | 141 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2014 | 175 | 0.030 |
Why?
|
| Access to Information | 1 | 2013 | 44 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 2240 | 0.030 |
Why?
|
| Workflow | 1 | 2013 | 133 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2014 | 418 | 0.030 |
Why?
|
| Genes | 1 | 1993 | 450 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2012 | 37 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 429 | 0.020 |
Why?
|
| Intussusception | 1 | 2013 | 54 | 0.020 |
Why?
|
| Body Mass Index | 1 | 1999 | 1708 | 0.020 |
Why?
|
| Gene Order | 1 | 2012 | 82 | 0.020 |
Why?
|
| Probability | 1 | 2013 | 335 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 679 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2015 | 418 | 0.020 |
Why?
|
| Recurrence | 1 | 2016 | 1465 | 0.020 |
Why?
|
| Patient Preference | 1 | 2013 | 135 | 0.020 |
Why?
|
| Inheritance Patterns | 1 | 2012 | 131 | 0.020 |
Why?
|
| Critical Care | 1 | 2017 | 688 | 0.020 |
Why?
|
| Eye Enucleation | 1 | 2011 | 54 | 0.020 |
Why?
|
| Length of Stay | 1 | 2017 | 1381 | 0.020 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1337 | 0.020 |
Why?
|
| Survivors | 1 | 2014 | 361 | 0.020 |
Why?
|
| Sex Factors | 2 | 2008 | 1384 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 1153 | 0.020 |
Why?
|
| Sequence Analysis, Protein | 1 | 2011 | 49 | 0.020 |
Why?
|
| Fetus | 1 | 2014 | 600 | 0.020 |
Why?
|
| Segmental Duplications, Genomic | 1 | 2010 | 81 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2014 | 636 | 0.020 |
Why?
|
| Pregnancy | 2 | 2018 | 7513 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2013 | 505 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 272 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 197 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 1990 | 53 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 1244 | 0.020 |
Why?
|
| Breast | 1 | 2011 | 218 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 1999 | 4799 | 0.020 |
Why?
|
| DNA, Recombinant | 2 | 1986 | 106 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2011 | 233 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 2 | 1986 | 198 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 542 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2008 | 87 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 3968 | 0.020 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2008 | 8 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2008 | 100 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2008 | 43 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 299 | 0.020 |
Why?
|
| Camptothecin | 1 | 2008 | 76 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2008 | 78 | 0.020 |
Why?
|
| Hydroxyurea | 1 | 2008 | 86 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2008 | 205 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 643 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 1814 | 0.020 |
Why?
|
| Neurons | 1 | 2017 | 2033 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2011 | 572 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 61 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2008 | 301 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2007 | 173 | 0.020 |
Why?
|
| Trioxsalen | 1 | 1986 | 2 | 0.020 |
Why?
|
| Furocoumarins | 1 | 1986 | 3 | 0.020 |
Why?
|
| Genes, Synthetic | 1 | 1986 | 12 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 969 | 0.020 |
Why?
|
| DNA, Superhelical | 1 | 1986 | 21 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1535 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2010 | 733 | 0.020 |
Why?
|
| Bone Density | 1 | 2008 | 370 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2005 | 118 | 0.010 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2005 | 92 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2005 | 295 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 183 | 0.010 |
Why?
|
| Cyclin D3 | 1 | 2004 | 11 | 0.010 |
Why?
|
| Cyclin D2 | 1 | 2004 | 15 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2005 | 115 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 866 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 261 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 203 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2007 | 482 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2004 | 50 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2004 | 90 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2004 | 67 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 364 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 2082 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2008 | 1002 | 0.010 |
Why?
|
| Calcium | 1 | 2008 | 1146 | 0.010 |
Why?
|
| Minichromosome Maintenance Complex Component 7 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Horseshoe Crabs | 1 | 1982 | 1 | 0.010 |
Why?
|
| Hemocyanins | 1 | 1982 | 27 | 0.010 |
Why?
|
| Interphase | 1 | 2001 | 42 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2001 | 34 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2001 | 95 | 0.010 |
Why?
|
| K562 Cells | 1 | 2001 | 100 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2001 | 169 | 0.010 |
Why?
|
| Fibrillins | 1 | 2001 | 31 | 0.010 |
Why?
|
| Copper | 1 | 1982 | 75 | 0.010 |
Why?
|
| Fibrillin-1 | 1 | 2001 | 61 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2002 | 247 | 0.010 |
Why?
|
| Drosophila melanogaster | 1 | 2006 | 837 | 0.010 |
Why?
|
| Rabbits | 1 | 2001 | 736 | 0.010 |
Why?
|
| Drosophila Proteins | 1 | 2006 | 761 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2001 | 199 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 905 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2001 | 711 | 0.010 |
Why?
|
| Chromatin | 1 | 2001 | 609 | 0.010 |
Why?
|
| Ukraine | 1 | 1997 | 14 | 0.010 |
Why?
|
| Teaching Materials | 1 | 1997 | 16 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1997 | 90 | 0.010 |
Why?
|
| Radiometry | 1 | 1997 | 41 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1997 | 110 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1997 | 145 | 0.010 |
Why?
|
| Family Practice | 1 | 1997 | 93 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 1997 | 109 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 1997 | 145 | 0.010 |
Why?
|
| Nocodazole | 1 | 1995 | 11 | 0.010 |
Why?
|
| Attitude to Health | 1 | 1997 | 261 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1995 | 186 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 1995 | 189 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1995 | 836 | 0.010 |
Why?
|
| Research Design | 1 | 1997 | 755 | 0.010 |
Why?
|
| Pheochromocytoma | 1 | 1990 | 39 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1990 | 80 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1995 | 1070 | 0.000 |
Why?
|
| DNA, Circular | 1 | 1986 | 18 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1995 | 1792 | 0.000 |
Why?
|
| Mollusca | 1 | 1982 | 11 | 0.000 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1982 | 23 | 0.000 |
Why?
|
| Arthropods | 1 | 1982 | 30 | 0.000 |
Why?
|
| Species Specificity | 1 | 1982 | 571 | 0.000 |
Why?
|
| Oxygen | 1 | 1982 | 580 | 0.000 |
Why?
|